Home › Drug Codes › J Codes › J0225 · Amvuttra
Updated July 1st, 2026

Amvuttra J Code: J0225

Injection, vutrisiran, 1 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J0225, effective October 1, 2026: $5,008.939 per HCPCS billing unit, down 0.1% from $5,012.599. From CMS's final file.

?
Medicare Payment Limit ?
$5,012.599
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$5,012.599
/ HCPCS billing unit · APC 9009
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, vutrisiran, 1 mg
HCPCS Added Date January 1, 2023
Manufacturer Alnylam Pharmaceuticals
Route of Administration Subcutaneous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection

About Amvuttra

Amvuttra is a medication aligned to the HCPCS J Code: J0225 for billing, pricing, and reimbursement purposes in the United States. This Genetic Disorder medication is administered via the subcutaneous route and manufactured by Alnylam Pharmaceuticals.

According to CMS Drug Use Information: Vutrisiran is used to treat a certain type of heart failure or nerve problems due to a certain inherited condition (transthyretin-mediated amyloidosis). This condition causes a protein that your body normally makes (transthyretin-TTR), to change shape and build up in different parts of your body, which can affect the nerves, heart, and stomach/intestines. This medication works by decreasing the buildup of TTR in your body. In people with heart failure, it may help lower the risk of death from heart disease, prevent the worsening of heart failure, and decrease the need to go to a hospital to treat heart failure.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
71336-1003-01 Amvuttra Alnylam Pharmaceuticals, Inc. 25 25 MG / 0.5 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

Amvuttra Pricing & Reimbursement

J0225 Private Payer Reimbursement
$5,009.42 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Amvuttra CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular
Not on the CMS JW / JZ list

CMS does not include Amvuttra (J0225) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J0225. Wastage billing guide →

Amvuttra Medically Unlikely Edits (MUE)

The most billing units of J0225 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient
25 units / day
= 25 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

Amvuttra Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis
Drug Class
Decreased RNA Integrity [PE]Increased Protein Breakdown [PE]RNASmall Interfering [CS]Small Interfering RNA [EPC]Transthyretin-directed RNA Interaction [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Amvuttra billing and coding guide?
Billing and coding information for Amvuttra can be found through Alnylam Pharmaceuticals, Inc.. Visit Here →
Are there any available Amvuttra patient assistance programs?
Amvuttra patient assistance information can be found through Alnylam Pharmaceuticals, Inc.. Visit Here →
Where can I find Amvuttra prescribing information?
Amvuttra prescribing information can be found at the link below: Visit Here →
Where can I find Amvuttra side effect information?
Information regarding Amvuttra's side effects can be found at MedlinePlus Visit Here →
Does billing Amvuttra require JZ/JW wastage modifiers?
CMS does not include Amvuttra (J0225) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J0225. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to Amvuttra.

J0222ONPATTROInjection, patisiran, 0.1 mgAlnylam PharmaceuticalsAdded October 1, 2019C9311WainuaInjection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)AstrazenecaAdded October 1, 2026C9172BEQVEZInjection, fidanacogene elaparvovec-dzkt, per therapeutic dosePfizerAdded October 1, 2024C9309ItvismaInjection, onasemnogene abeparvovec-brve, per treatmentNovartis Gene TherapiesAdded April 1, 2026J0223GIVLAARIInjection, givosiran, 0.5 mgAlnylam PharmaceuticalsAdded July 1, 2020J0224OXLUMOInjection, lumasiran, 0.5 mgAlnylam PharmaceuticalsAdded July 1, 2021J0584CRYSVITAInjection, burosumab-twza 1 mgKyowa KirinAdded January 1, 2019J1203POMBILITIInjection, cipaglucosidase alfa-atga, 5 mgAmicus TherapeuticsAdded April 1, 2024J1413ELEVIDYSInjection, delandistrogene moxeparvovec-rokl, per therapeutic doseSarepta TherapeuticsAdded January 1, 2024J1426AMONDYS-45Injection, casimersen, 10 mgSarepta TherapeuticsAdded October 1, 2021